CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with Rituximab
- 1 October 2000
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 65 (2) , 171-173
- https://doi.org/10.1002/1096-8652(200010)65:2<171::aid-ajh14>3.0.co;2-z
Abstract
B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. Am. J. Hematol. 65:171–173, 2000.Keywords
This publication has 5 references indexed in Scilit:
- Anti–B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term OutcomeBlood, 1998
- Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disordersThe Lancet, 1998
- Regulation and Processing of a Precursor Form of Eosinophil Granule Major Basic Protein (ProMBP) in Differentiating EosinophilsBlood, 1998
- Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 ImmunotoxinAnnals of Internal Medicine, 1997
- Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantationBlood, 1988